

LINITED STATES PARENTE AND TRADEMARK OFFICE.

United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/935,316	08/22/2001	Ching-Leou Teng	ISIS-4824	1463
34138	7590 10/06/2003		EXAMINER	
COZEN O'CONNOR, P.C. 1900 MARKET STREET PHILADELPHIA, PA 19103-3508		ANGELL, JON E		
			ART UNIT	PAPER NUMBER
			1635	

DATE MAILED: 10/06/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)			
	09/935,316	TENG ET AL.			
Office Action Summary	Examiner	Art Unit			
·	J. Eric Angell	1635			
The MAILING DATE of this communication app					
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPL' THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a y within the statutory minimum of thi will apply and will expire SIX (6) MO, cause the application to become A	reply be timely filed ty (30) days will be considered timely. NTHS from the mailing date of this communication. BANDONED (35 U.S.C. § 133).			
1) Responsive to communication(s) filed on					
	· iis action is non-final.				
3) Since this application is in condition for allows		atters prosecution as to the merits is			
closed in accordance with the practice under Disposition of Claims					
4)⊠ Claim(s) <u>1-24</u> is/are pending in the application	1.				
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
6)☐ Claim(s) is/are rejected.					
7) Claim(s) is/are objected to.					
8) Claim(s) <u>1-24</u> are subject to restriction and/or election requirement.					
Application Papers					
9)☐ The specification is objected to by the Examiner.					
10) The drawing(s) filed on is/are: a) accept					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11)☐ The proposed drawing correction filed on is: a)☐ approved b)☐ disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action. 12)☐ The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120 13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
1.☐ Certified copies of the priority document	s have been received				
2.☐ Certified copies of the priority document		Application No.			
3. Copies of the certified copies of the prior					
application from the International Bu * See the attached detailed Office action for a list	reau (PCT Rule 17.2(a)).				
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
 a) ☐ The translation of the foreign language pro 15)☐ Acknowledgment is made of a claim for domest 	* *				
Attachment(s)					
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲 Notice of	Summary (PTO-413) Paper No(s) Informal Patent Application (PTO-152)			

DETAILED ACTION

Claims 1-24 are pending and are addressed herein.

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - Claims 1-15, drawn to an oral formulation, classified in class 514, subclass 2 or class 514, subclass 44.
 - II. Claims 16-24, drawn to a method for enhancing the intestinal absorption of a drug in an animal comprising administering the formulation of invention I, classified in class 514, subclass 2 and class 514, subclass 44.

The inventions are distinct, each from the other because of the following reasons:

2. Inventions I and II are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the product can be used in a materially different method of use such as delivering a compound into a cell in a subject or delivering a compound to a cell in vitro. Furthermore, the method could be practiced with a materially different product, such as lipofectamine.

Art Unit: 1635

Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II, restriction for examination purposes as indicated is proper.

3. This application contains claims directed to the following patentably distinct species the claimed invention:

Drugs:

See the species of drugs set forth in claims 2 and 21 (from protein to ACE inhibitor)

Penetration enhancers (claims 4 and 22):

Fatty acid, bile acid, chelating agent, and non-chelating non-surfactant

Further species election of one of the following appropriate subspecies is also required:

For Fatty acids:

See claim 5 (from arachadonic acid to a monoglyceride)

For Bile acids:

See claim 6 (from cholic acid to polyoxyethylene-9-laurel ether)

For Chelating agents:

See claim 7 (EDTA to N-amino acyl...)

For Non-chelating non-surfactants:

Application/Control Number: 09/935,316

Art Unit: 1635

See claim 8

Bioadhesives:

See claims 10 and 23

Cellulose derivatives:

See claim 11

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, claims 1-24 are generic.

Page 4

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to J. Eric Angell whose telephone number is (703) 605-1165. The examiner can normally be reached on M-F (8:00-4:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, John L. LeGuyader can be reached on (703) 308-0447. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

J. Eric Angell Art Unit 1635 DAVET. NGUYEN PRIMARY EXAMINER